Hasselt, Belgium and Chepstow, UK: 15 November 2016 − Apitope, the clinical stage company focused on treating the underlying cause of autoimmune diseases, is pleased to announce that Apitope is featured in the 60 Years of Immunology report by the British Society for Immunology (BSI).
In the report, Professor David Wraith, Founder & Chief Scientific Officer of Apitope, discusses the importance of moving away from non-specific immunosuppressive drugs that make patients susceptible to infections as well as cancers and instead help the immune system correct itself using antigen specific immunotherapy.
The BSI is one of Europe’s largest and oldest societies and is dedicated to supporting immunology and immunologists. It was founded 60 years ago in 1956 by a small group of hard working, visionary immunologists, who wanted to come together to share ideas and encourage the study of immunology. With over 3,000 members, the society’s mission is to promote excellence in immunological research, scholarship and clinical practice in order to improve human and animal health. The BSI publishes the journals, Immunology and Clinical & Experimental Immunology.
Dr Keith Martin, CEO of Apitope, commented: “It is a great honour to be included the BSI’s report highlighting the key advances in immunology including the use of antigen specific therapy pioneered by our CSO, Professor David Wraith, to celebrate the Society’s 60 years. Apitope has built an exciting portfolio of product candidates with two programmes in the clinic; one for multiple sclerosis and another for Graves’ disease whilst a peptide therapy for Factor VIII inhibitor patients is being prepared for initiation of clinical trials. We have a pipeline of seven programmes in clinical and preclinical development for the treatment of multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. These have the potential to be uniquely disease-modifying therapies.”